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ABSTRACT
Growing evidence supports the implication of DYRK1A in the
development of cognitive deficits seen in Down syndrome (DS) and
Alzheimer’s disease (AD). We here demonstrate that pharmacological
inhibition of brain DYRK1A is able to correct recognition memory
deficits in three DS mouse models with increasing genetic complexity
[Tg(Dyrk1a), Ts65Dn, Dp1Yey], all expressing anextra copyofDyrk1a.
Overexpressed DYRK1A accumulates in the cytoplasm and at the
synapse. Treatment of the three DS models with the pharmacological
DYRK1A inhibitor leucettine L41 leads to normalization of DYRK1A
activity and corrects the novel object cognitive impairment observed in
these models. Brain functional magnetic resonance imaging reveals
that this cognitive improvement is paralleled by functional connectivity
remodelling of core brain areas involved in learning/memory
processes. The impact of Dyrk1a trisomy and L41 treatment
on brain phosphoproteins was investigated by a quantitative
phosphoproteomics method, revealing the implication of synaptic
(synapsin 1) and cytoskeletal components involved in synaptic
response and axonal organization. These results encourage the
development of DYRK1A inhibitors as drug candidates to treat
cognitive deficits associated with DS and AD.
KEY WORDS: DYRK1A, Kinase inhibitor, Leucettine, Down
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INTRODUCTION
Down syndrome (DS) results from the trisomy of human
chromosome 21 (HSA21). It is still the most frequent intellectual
disability, affecting 1 newborn per 700 births. Among the most
common DS features are hypotonia, dysmorphic features and
intellectual disability (Sureshbabu et al., 2011; Morris et al., 1982).
Although children with DS show good socialization skills –
encompassing social relations, friendship and leisure activities –
they exhibit difficulties in communication abilities, i.e. the daily use
of receptive, expressive and written language (Marchal et al., 2016).
They experience troubles in daily life skills, such as self-caring,
eating, toileting, dressing, behaving safely, and conceptualizing
time and money. Improving the intellectual quotient of DS people
would allow them to achieve more independence, increase their
vigilance and globally improve their quality of life.
Among candidate genes explaining intellectual disabilities in DS
people, the dual specificity tyrosine-phosphorylation-regulated
kinase 1A, DYRK1A, is located in the DS chromosome 21 critical
region (Walte et al., 2013; Duchon and Herault, 2016). It encodes
a serine/threonine kinase which has numerous substrates. Two
nuclear localization signals confer nuclear activity to this kinase
(Alvarez et al., 2007), through interactions with transcription factors
including GLI1 (Mao et al., 2002), RNA POL II (Di Vona et al.,
2015) or splicing factors like cyclin L2 (Graaf et al., 2004). In the
cytoplasm, DYRK1A phosphorylates cytoskeletal substrates such
as β-tubulin, MAP1A or MAP1B (Ori-McKenney et al., 2016;
Murakami et al., 2012; Scales et al., 2009). DYRK1A plays a role in
cell cycle regulation by phosphorylating the cyclin-dependent
kinase (CDK) inhibitor KIP1 (also known as CDKN1B) in cultured
hippocampal neurons and in embryonic mouse brain (Soppa et al.,
2014) and LIN52 in vitro (Litovchick et al., 2011). Through its
‘priming’ activity for glycogen synthase kinase 3β (GSK-3β)-
dependent phosphorylation, DYRK1A regulates the nuclear/
cytoplasmic localization of the NFAT transcription factors
(Arron et al., 2006). At the synaptic level, DYRK1A binds to
N-methyl-D-aspartate receptor subunit 2A (GLUN2A; also known
as GRIN2A) and synaptojanin 1 (SYNJ1) (Chen et al., 2014; Grau
et al., 2014) and phosphorylates amphyphysin 1 (Murakami et al.,
2012) and GLUN2A (Grau et al., 2014). These are examples of
different biological brain functions controlled by DYRK1A which
are probably dysregulated when DYRK1A is overexpressed in DS,
leading to cognitive impairments.
Several mouse models overexpressing DYRK1A have been
described. The first one, Tg(CEPHY152F7)12Hgc, carries a single
copy of a yeast artificial chromosome (YAC) containing a 570 kb
fragment of human DNA encompassing TTC3, DYRK1A and
KCNJ6. This model shows no strong defect in spatial learning and
memory, but displays less crossing of the site where the platform
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Strasbourg, 67400 Illkirch, France. 5ManRos Therapeutics, Perharidy Research
Center, 29680 Roscoff, Bretagne, France. 6Faculty of Medicine/Cancer Sciences &
Clinical and Experimental Medicine, University of Southampton, Center for
Proteomic Research, Life Sciences Building 85, Highfield, Southampton SO17 1BJ,
UK. 7Laboratory of Engineering, Informatics and Imaging (ICube), Integrative
multimodal imaging in healthcare (IMIS), UMR 7357, and University Hospital
Strasbourg, Department of Biophysics and Nuclear Medicine, University of
Strasbourg, 67400 Illkirch, France. 8Department of Radiology, Medical Physics,
Medical Center – University of Freiburg, Breisacher Strasse 60a, 79106 Freiburg,
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(Smith et al., 1997). Another model, Tg(MT1A-Dyrk1a)#Xest
(#=9 or 33), was produced by expressing the Dyrk1a rat
complementary DNA (cDNA) under the control of the
metallothionein 1a exogenous promoter (Altafaj et al., 2001).
These mice demonstrated impairments in neuromotor development
and hyperactivity evaluated in treadmill performance and rotarod
tests (Martínez de Lagrán et al., 2004). They also display defects in
visuospatial learning and memory in the MWM task (Martínez de
Lagrán et al., 2004; Pons-Espinal et al., 2013), as well as in
recognition memory revealed in the novel object recognition (NOR)
task (de la Torre et al., 2014). A third model, Tg(DYRK1A)36Wjs,
was generated using a bacterial artificial chromosome (BAC)
containing the human DYRK1A gene. DYRK1A triplication leads to
alterations in synaptic transmission with an increase in long-term
potentiation (LTP) and a decrease in long-term depression (LTD).
The transgenic mice are also deficient in the MWM task, suggesting
spatial learning and memorization disabilities (Ahn et al., 2006).
Although the human YAC and BAC transgenic mice exhibit
features similar to those seen in DS patients, they carry an extra
copy of human/rat DYRK1A gene, which could lead to biased
phenotypes, as optimal expression and functionality of the human/
rat protein cannot be ensured in a mouse background. Therefore, a
BAC transgenic model with the entire Dyrk1a murine gene,
Tg(Dyrk1a)189N3Yah [hereafter referred to as Tg(Dyrk1a)], was
created (Guedj et al., 2012). This model shows alterations in
short-term memory in the Y-maze task, and in spatial memory
in the MWM task (Souchet et al., 2014). Deficits in cortical
synaptic plasticity were also observed (Thomazeau et al., 2014).
Comparable impairments were seen in the Ts(1716)65Dn model
(hereafter referred to as Ts65Dn), a mouse model trisomic for
almost 13.4 Mb, homologous to HSA21 and containing DYRK1A
(Reeves et al., 1995). Spatial memory, especially reversal learning
reflecting cognitive flexibility, was altered in the Water T-maze
test and in the reversal version of the MWM (Olmos-Serrano et al.,
2016). Although the Ts65Dn model has been widely used to
study DS features, it carries a triplication of genes located in a
subcentromeric region of mouse chromosome 17 (MMU17) which
are not syntenic to any HSA21 genes (Duchon et al., 2011).
A complete DS model, Dp1Yey, was thus produced, which is
trisomic for 22.9 Mb, spanning the entire HSA21 region on
MMU16 (Li et al., 2007). Dp1Yey mice are less well performing
than control mice in the MWM task and display context-associated
learning deficits in the fear conditioning test (Yu et al., 2010).
Reducing DYRK1A overdosage leads to correction of several DS
traits, demonstrating the major implication of this kinase in DS.
Indeed, normalization of DYRK1A expression attenuates spatial
learning as well as associative memory defects, and rescues LTP in
the Ts65Dn model (García-Cerro et al., 2014; Altafaj et al., 2013).
In addition, reversal to two DYRK1A copies in Dp1Yey mice
enhances working and associative learning performance assessed in
the T-maze and contextual fear-conditioning tests, respectively
(Jiang et al., 2015). Furthermore, epigallocatechin gallate (EGCG),
a natural polyphenol found in coffee, cocoa and green tea, reported
to inhibit DYRK1A, restores intellectual capacities of trisomic mice
(Guedj et al., 2009; de la Torre et al., 2014). EGCG has undergone a
phase 2 clinical trial (de la Torre et al., 2016). However, EGCG also
interacts with the cannabinoid receptor 1 (CNR1) (Korte et al.,
2010). This receptor modulates the release of neurotransmitters in
various brain areas, such as the prefrontal cortex and hippocampus,
thereby controlling memory, cognition processes and mood.
Interaction of EGCG with CNR1 might thus affect memory,
cognition and pain perception, leading to psychiatric disorders
(Freund et al., 2003; Wilson and Nicoll, 2002), compromising its
therapeutic use. Furthermore, DYRK1A is less sensitive to EGCG
[half-maximal inhibitory concentration (IC50), 0.33 µM] than
vimentin (IC50, 0.003 µM) and the laminin receptor (IC50,
0.04 µM) (Khan et al., 2006; Yang et al., 2009). Cognitive
restoration in trisomic mice by EGCG might thus be due to
inhibition of targets other than DYRK1A. Consequently,
alternative pharmacological inhibitors have started to emerge
(Kim et al., 2016; Nakano-Kobayashi et al., 2017; Nguyen et al.,
2017). Nevertheless, all available results clearly demonstrate
the implication of DYRK1A in DS intellectual deficiencies and
the beneficial effects of its inhibition on the correction of
cognitive deficits.
DYRK1A has become a major screening target for the
development of selective and potent pharmacological inhibitors
(Smith et al., 2012; Stotani et al., 2016; Nguyen et al., 2017).
We here investigated the effects of a relatively selective DYRK1A
inhibitor, leucettine L41 (hereafter referred to as L41) in three
different trisomic mouse models with increasing genetic
complexity: Tg(Dyrk1a), Ts65Dn and Dp1Yey. Leucettines are
derived from the marine sponge alkaloid Leucettamine B
(Debdab et al., 2011; Tahtouh et al., 2012). The chemically
synthesized L41 displays a high selectivity for DYRK1A but also
DYRK1B, DYRK2 and some Cdc2-like kinases (CLKs) (Fig. 1).
It acts by competing with ATP binding to the kinase catalytic site.
We here establish a proof of concept that pharmacological
inhibition of brain DYRK1A is able to correct NOR cognitive
impairment in three DS models with increasing genetic complexity.
We show, via brain functional magnetic resonance imaging (fMRI)
in Dp1Yey, the most complete mouse model of DS, that such
cognitive improvement is paralleled by significant functional
connectivity remodelling of core brain areas involved in learning
andmemory processes. Furthermore, phosphoproteomic analyses in
the Tg(Dyrk1a) model unravelled brain DYRK1A targets for which
phosphorylation increases with DYRK1A overdosage and
decreases following L41 treatment. These novel substrates, such
as synapsin 1 (SYN1), also found in the phosphoproteomic analyses
of Ts65Dn, the most used DS model, bring new insight into the role
of DYRK1A, and allow us to propose some dysregulated biological
processes related to axonal organization and synaptic response which
are responsible for cognitive deficits associated with DS.
RESULTS
Leucettines restore cognitive function, assessed in the
NOR test, through kinase inhibition in three DS mouse
models overexpressing DYRK1A
To investigate the importance of DYRK1A in cognitive deficits
shown by transgenic mouse models of DS, we used a series of low
molecular weight pharmacological inhibitors, collectively known as
leucettines (Debdab et al., 2011; Tahtouh et al., 2012; T. Tahtouh,
unpublished). We selected the well-characterized leucettine L41 as
an archetype of this inhibitor family (Fig. 1) and L43, a closely
related analogue which displays little kinase inhibitory action.
Because both compounds were found to inhibit CNR1 (T. Tahtouh,
unpublished), we also used L99, a DYRK1A inhibitor lacking
activity on CNR1 (Fig. 1). To ensure its brain bioavailability,
L41 was dosed following acute intraperitoneal (i.p.) injection in
Tg(Dyrk1a) and wild-type (wt) mice. Plasma half-life was∼45 min,
and the inhibitor reached a maximum brain concentration at 20 min,
and was eliminated 2 h later. No differences in L41 pharmacokinetics
or biodistribution were observed between transgenic and wt
mice (Fig. S1).
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We used three mouse models of DS: Tg(Dyrk1a), which expresses
a single additional copy of DYRK1A (Guedj et al., 2012); and
Ts65Dn (Reeves et al., 1995) and Dp1Yey (Li et al., 2007), which
carry MMU16 segments encompassing Dyrk1a, with 89 and 101
genes homologous to HSA21, respectively (Gupta et al., 2016).
Using the NOR test, we first evaluated the effects on Tg(Dyrk1a)
animals following daily i.p. treatment with L41 (20 mg/kg) for
5, 12 or 19 days (Fig. 2A). As expected, untreated wt mice
discriminated the novel over the familiar object. L41 treatment for
5, 12 or 19 days had no effect on the performance of wt animals.
Untreated Tg(Dyrk1a) mice were unable to discriminate the novel
over the familiar object (de la Torre et al., 2014) (Fig. 2A). In
contrast, L41-treated Tg(Dyrk1a) mice preferentially explored the
novel object, thus reverting to the behaviour of wt animals. This
recovery was fully observed following 19 days of treatment, but was
consistently or only marginally seen following 12 and 5 days of
treatment, respectively (Fig. 2A). In other words, a minimum of
12 days of daily L41 treatment was necessary for full recovery in the
NOR test.
These experiments were repeated (daily i.p. treatment for
19 days) with the kinase-inactive/CNR1-active L43 and the
kinase-active/CNR1-inactive L99 leucettines (Fig. 2B). Results
clearly showed the beneficial behavioural effects of L99 (Fig. 2B,
right) and the lack of effects of L43 (Fig. 2B, left), demonstrating
that the rescuing activity of leucettines derives from kinase
inhibition rather than CNR1 antagonism.
We next ran the same experiments in Ts65Dn and Dp1Yey
animals (Fig. 2C). Daily i.p. treatment with L41 for 19 days led to
rescue in the NOR test. Intriguingly, L41 treatment had no restoring
effect on working memory (Fig. S2A), nor on place memory in
Tg(Dyrk1a) mice (Fig. S2B), as assessed in the Y-maze and place
object location paradigms, respectively.
L41 treatment has a global effect on brain functional
connectivity measured by resting state fMRI
To noninvasively investigate whether DYRK1A kinase activity
alters the brain functional connectivity (FC) and to reveal possible
circuitry-based mechanisms underlying cognitive improvements
induced by L41, we performed brain resting state fMRI (rsfMRI)
experiments in vehicle or L41-treated Dp1Yey and wt mice.
The brain connectivity patterns associated with default mode
network (DMN) – the main functional circuitry describing the
brain’s intrinsic activity at rest (Raichle, 2015) – were mapped
comparatively for each experimental group (Fig. 3A-a,b,B-a,b) via
seed-based analysis. The seed used for generating DMN was the
retrosplenial cortex (RSP), considered as the mouse DMN core area.
DMN configuration obtained for the wt vehicle-treated group
(Fig. 3A-a) served as a control pattern and encompassed the
midline cortical areas [RSP, posterior parietal association areas
(PTLp), temporal association areas, visual areas] as well as the
rostral and medial anterior cingulate cortex (ACA) and hippocampal
formation (HF) as previously described in mice (Sforazzini
et al., 2014; Stafford et al., 2014). This DMN-like configuration
was only minimally impacted by L41 treatment in wt animals
(Fig. 3A-c,d), by decreasing the RSP connectivity with limited
hippocampal (HF) areas.
In Dp1Yey mice, trisomy strongly influenced DMN architecture
(Fig. 3B-a) by altering its pattern along midline cortical areas,
highlighting the pathological features of Dp1Yey brain, as compared
with wt brains (Fig. 3A-a). Notably, Dp1Yey mice show reversed
connectivity features of RSP (the core area of DMN) towards the
rostrofrontal cortical regions, including ACA [Fig. 3A-a versus B-a;
switch from positive correlations (red/yellow scale) to negative
correlations (blue scale)]. Intergroup statistics (vehicle-treated wt
versus vehicle-treated Dp1Yey; Fig. S3) revealed diminished
RSP-ACA connectivity in Dp1Yey animals compared with
controls (Fig. S3A), while strengthening the local connectivity
around the RSP seed (Fig. S3B). Concurrently, the RSP of Dp1Yey
vehicle animals showed increased connectivity to limbic areas of
basal forebrain [i.e. pallidum (PAL)] when compared with that of
the wt vehicle group (Fig. S3B).
L41 treatment of Dp1Yey mice rescued this altered DMN
pattern (Fig. 3B-b), prominently acting to significantly increase the
FC of the RSP with the ACA, prefrontal cortex (PFC) and ventral
HF (group statistics in Fig. 3B-d, orange/red) and to reduce FC
with subcortical regions including the thalamus (TH) and PAL
(Fig. 3B-d, green/blue).
To further reveal FC signatures of L41 action in Dp1Yey mice we
evaluated the connectivity, across the whole brain, for several key
brain areas involved in learning and memory [hippocampal CA1
and dentate gyrus (DG) areas, perirhinal cortex (PERI) and ACA].
Group statistical analysis of FC maps highlighted overall restricted
Fig. 1. Chemical structure and selectivity of the leucettines
used in this study. Selectivity of leucettines L41, L43 and L99
was assessed in vitro on 16 recombinant kinases, and in a
cellular CB1 annexin assay. Dose-response curves provided
IC50 values (reported in µM). –, no inhibition at 10 µM.
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effects of L41 on brain FC of wt animals (Fig. 3C-a-d) but robust
L41-dependent brain FCmodifications in theDSmodel (Fig. 3D-a-d).
Acting at the hippocampal level, L41 treatment triggered robust
changes in CA1 and DG connectivity in Dp1Yey mice (Fig. 3D-a,b).
The CA1 strengthened its FC with the PFC and ACA (Fig. 3D-a,
orange/red) and decreased its functional communication with the
ventral HF (subiculum) and thalamic nuclei (Fig. 3D-a, green/blue).
The strongest L41-triggered DG connectivity modifications were
identified along the DG-RSP functional pathway in Dp1Yey mice
(Fig. 3D-b). A divergent and limited effect of decreased CA1-ACA
connectivity was measured in wt mice, after L41 treatment
(Fig. 3C-a, green/blue), and the DG altered its connectivity towards
the TH and superior colliculus (SC) in wt animals.
Furthermore, L41 treatment triggered remodelling of
functional cross-talk between the PERI and the HF, RSP and
PTLp in Dp1Yey animals (Fig. 3D-c), while acting primarily
on PERI-TH connectivity in wt animals (Fig. 3C-c). Group
statistics additionally revealed a selective impact of L41 on
ACA connectivity in Dp1Yey mice (Fig. 3D-d), significantly
modifying its patterns towards the PFC (decrease), RSP
(increase), SC (increase) and hypothalamic (HY) areas
(decrease). Meanwhile, L41 induced limited effects in wt mice,
by decreasing ACA-PFC connectivity (Fig. 3C-d). Overall, these
results indicate the potential of L41 to act at a circuitry level,
modifying the global brain FC in Dp1Yey mice, which are
strongly susceptible to its effects.
Fig. 2. DYRK1A-specific inhibitors rescue NOR deficits induced in Tg(Dyrk1a), Ts65Dn and Dp1yey trisomic mice. (A) Duration of treatment.
NOR test results for Tg(Dyrk1a) mice treated with L41 or vehicle for 5, 12 or 19 days. Percentage object exploration by sniffing was determined for each
object after a 24 h retention delay (familiar object, open symbol; novel object, filled symbol). NOR results of three Tg(Dyrk1a) cohorts treated with L41 for 5 (left),
12 (centre) or 19 (right) days. Tg(Dyrk1a) and Ts65Dn treated animals spent more time exploring the novel object compared with control mice, showing a rescue
of their recognition memory. Left: 5 days treatment induced a NOR rescue in Tg(Dyrk1a) animals [wt: n=15, P<0.001; treated wt: n=15, P<0.001; untreated
Tg(Dyrk1a): n=11,P=0.8; treated Tg(Dyrk1a): n=13,P=0.02]. Centre: amore consistent rescuewas obtained after 12 days of L41 treatment [not treated wt: n=12,
P<0.001; treated wt: n=15, P=0.11; untreated Tg(Dyrk1a): n=8, P=0.76; treated Tg(Dyrk1a): n=11, P<0.001]. Right: rescue obtained after 19 days of L41
treatment: the exploration was significantly different for wt (n=15, P<0.001), treated wt (n=15, P<0.001) and treated Tg(Dyrk1a) (n=15b, P<0.001) mice, but
not for nontreated transgenic mice (n=13, P=0.64). (B) Treatment with L43 (left) and L99 (right). L99 treatment induced a cognitive rescue in the Tg(Dyrk1a) mice,
whereas L43 treatment had no effect. L99 (right): [wt: n=10, P=0.02; treated wt: n=12, P=0.003; Tg(Dyrk1a): n=12, P=0.01; treated Tg(Dyrk1a): n=9, P<0.001].
L43 (left): [wt: n=12, P=0.008; treated wt: n=7, P=0.9; Tg(Dyrk1a): n=13, P=0.91; treated Tg(Dyrk1a): n=12, P=0.71]. (C) Ts65Dn and Dp1yey models. Left: in the
Ts65Dn study, a significant statistical difference was observed for untreated wt (n=10, P<0.001), treated wt (n=8, P=0.009) and treated Ts65Dn (n=11, P=0.002),
but not for untreated Ts65Dn animals (n=9, P=0.08). Right: L41 also normalizes the recognition memory of Dp1Yey mice (wt: n=13, P=0.04; treated wt: n=14,
P=0.02; Dp1Yey: n=7, P=0.98; treated Dp1Yey: n=11, P=0.03). Data are represented as mean±s.e.m. with individual points per animal. Statistical analysis was
performed with the two-way ANOVA test, Tukey post hoc. n.s., not significant. *P<0.05, **P<0.01, ***P<0.001.
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Increased DYRK1A expression and catalytic activity in DS
models: leucettines normalize DYRK1A activity
To validate the Tg(Dyrk1a) and Ts65Dn models in terms of
DYRK1A expression and function, we first verified the expression
levels of Dyrk1a mRNA (Fig. 4A) and DYRK1A protein (Fig. 4B)
in brains derived from control or L41-treated animals (19 days,
daily i.p.). Total mRNAs were extracted from brains and Dyrk1a,
Gsk-3b and Rplp0 mRNAs were quantified by quantitative
polymerase chain reaction (qPCR) with specific primers. Results
showed the expected ∼1.5-fold increase in Dyrk1a mRNA levels
(normalized with respect to Gsk-3b and Rplp0) in both transgenic
models compared with their wt littermates. L41 treatment for
19 days did not modify Dyrk1a mRNA levels (Fig. 4A). DYRK1A
protein levels were also increased in transgenic mice models
Fig. 3. Influence of L41 on mouse brain functional connectivity (FC) patterns mapped via rsfMRI. (A,B) Default mode network (DMN) pattern in wt (a)
and Dp1Yey (b) animals, mapped using the RSP cortex (core hub of DMN) as a seed region. A-a shows the typical DMN-like pattern observed in mice,
spatially covering the middle rostrocaudal cortical axis of wt animals treated with vehicle, connecting the RSP and ACA. As shown in B-b, L41 treatment in
wt animals slightly modifies the DMN patterns compared with wt-vehicle (see also statistics in A-c, sagittal view and A-d, coronal view; two-tailed Student’s t-test,
P<0.01). Red-orange scale quantifies the areas in which L41 treatment results in increased FC of wt-L41 compared with wt-vehicle. Blue-green scale
indicates areas with decreased RSP connectivity after L41 treatment, compared with vehicle-treated wt mice. B-a demonstrates strongly altered DMN in
vehicle-treated Dp1Yey compared with wt vehicle-treated animals (A-a, wt-vehicle), highlighting the pathological connectivity features of the mutant animals.
As shown in B-b, L41 treatment in mutant Dp1Yey animals (DP16-L41) strongly modifies the DMN, restoring the positive correlations (red) of the RSP with
the frontal brain areas (arrows, B-b). Voxel-wise statistics shown in B-c and B-d indicate, in red-orange, the areas in which L41 treatment results in increased
FC of the DP16-L41 group compared with the DP16-vehicle group. Blue-green scale indicates areas with decreased RSP connectivity after L41 treatment,
compared with the vehicle-treated group mutant mice. In A-a,b and B-a,b, red indicates the positively correlated areas (0.1 to 0.5 correlation coefficients);
blue indicates negatively correlated areas (–0.1 to –0.5 correlation coefficients). (C,D) FC patterns in wt (C) and Dp1Yey (D) animals after L41 treatment:
C-a, CA1 FC; C-b, dentate gyrus FC; C-c, perirhinal cortex FC; C-d, ACA FC (two-tailed Student’s t-test, P<0.01). Red-orange shows the brain areas in which
L41 treatment results in increased FC; blue-green indicates areas with decreased connectivity after L41 treatment, compared with vehicle-treated mice.
ACA, rostral and medial anterior cingulate cortex; Cb, cerebellum; HF, hippocampal formation; HY, hypothalamus; PAL, pallidum; PFC, prefrontal cortex; PTLp,
posterior parietal association areas; RSP, retrosplenial cortex; SC, superior colliculus; TH, thalamus.
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compared with control wt animals, as shown by western blotting
(WB) of total brain proteins, whereas GSK-3α/β and β-actin levels
remained at identical levels in transgenic and wt mice brains
(Fig. 4B). L41 treatment had no effect on the expression of
DYRK1A and GSK-3α/β. We next measured DYRK1A catalytic
activities from transgenic and wt brain protein extracts (Fig. 4C).
After 19 days of L41 or vehicle treatment, GSK-3α/β activity
remained identical in the brains of transgenic and wt mice (data not
shown), and was thus used to normalize the DYRK1A kinase
activity. As expected, DYRK1A activity was elevated by ∼1.5- to
1.8-fold in transgenic brains compared with wt brains (Fig. 4C).
L41 treatment did not reduce DYRK1A activity in wt mice
brains, but reduced DYRK1A activity by ∼30% in the brains of
Tg(Dyrk1a) and Ts65Dn animals, essentially down to the level of
control counterparts. DYRK1A kinase activity was thus normalized
by L41 treatment (Fig. 4C). In other words, although basal DYRK1A
activity in trisomic and disomic mice brains was insensitive to L41,
only excess DYRK1A activity in trisomic mice brains appeared to
be sensitive to L41. To verify that all brain DYRK1A activity can,
in principle, be inhibited by L41, DYRK1A was extracted and
immunopurified from the brains of untreated wt and both transgenic
animals. DYRK1A kinase activities were assayed in vitro in the
presence of increasing concentrations of L41. Results showed that
the DYRK1A of wt and transgenic animal brains can be almost
fully inhibited in vitro with essentially identical dose-response
curves (Fig. 4D).
DYRK1A activity was measured following immunoprecipitation
(and normalization on the basis of GSK-3α/β activity measured in the
same samples) from brain extracts of wt and Tg(Dyrk1a) animals
treated daily for 5, 12 or 19 days (Fig. 5A-C) with L41, or for 19 days
with kinase-inactive L43 (Fig. 5D). As expected, DYRK1A activity
was increased in Tg(Dyrk1a) versus wt brains. Tg(Dyrk1a) brain
DYRK1A activity was normalized after treatment with L41 for 12
and 19 days, but not after 5 days of L41 treatment, nor after 19 days of
L43 treatment. These results correlate with L41-induced DYRK1A
activity normalization (Fig. 5) and cognitive rescue (Fig. 2).
In all previous experiments, brains were collected 1 h after the last
leucettine treatment. We wondered about the persistence of the
effects of L41 after the last injection (Fig. 6). Tg(Dyrk1a) and wt
animals were treated with L41/vehicle daily for 19 days. NOR tests
were run and brains collected 24 h or 48 h after the last L41
treatment. DYRK1A catalytic activity was dosed in Tg(Dyrk1a) and
wt mice brains. As expected, wt brain DYRK1A activity was
insensitive to L41 treatment. Tg(Dyrk1a) brain DYRK1A activity
was increased compared with control wt brain DYRK1A activity
(Fig. 6A,C), and normalized to wt levels 24 h after the last L41
Fig. 4. Dyrk1a mRNA and DYRK1A protein
expression, and catalytic activity in Tg(Dyrk1a)
and corresponding wt mice brains, and in Ts65Dn
and corresponding wt mice brains. (A) mRNA
expression. Total RNA was extracted, purified and
reverse transcribed into cDNA. mRNA expression of
Dyrk1a, Gsk-3b and reference Rplp0 was quantified
by qPCR from the amplification of cDNA with specific
primers (one primer annealing to an exon-exon
junction). Results are presented as mean±s.e. of
four to six measurements and are shown relative
to Rplp0 expression, normalized to wt Gsk-3b
expression. (B) Protein expression. Total proteins
were extracted, resolved by SDS-PAGE and analysed
by WB using antibodies directed against DYRK1A,
GSK-3α/β and actin (loading control). (C) DYRK1A
catalytic activity. DYRK1A was purified from brain
extracts by immunoprecipitation and GSK-3α/β was
purified by affinity chromatography on axin-agarose
beads. Activities of the purified kinases were assayed
in triplicate in a radioactive kinase assay using
specific peptide substrates, and are reported after
normalization with wt GSK-3α/β activities (mean±s.e.).
(D) In vitro DYRK1A kinase activity. The catalytic
activity of DYRK1A immunoprecipitated from the
brains of Tg(Dyrk1a) and Ts65Dn mice and their
respective controls was assayed in the presence of a
range of L41 concentrations.
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treatment (Fig. 6A). In contrast, L41 had no more effects 48 h after
the last treatment (Fig. 6C). In terms of restoration of cognitive
abilities, the NOR tests revealed that Tg(Dyrk1a) deficits were still
corrected 24 h, but not 48 h, after the last L41 treatment (Fig. 6B,D).
Because L41 is essentially undetectable in brain extracts 2 h after
the acute i.p. injection, it might be protected from degradation once
bound to DYRK1A or it could have been metabolized to an
unidentified, stable active inhibitor.
Overexpressed DYRK1A accumulates in cytoplasm and
synapse: differential subcellular L41 distribution
We next investigated the subcellular distribution of DYRK1A in the
brains of Tg(Dyrk1a) and wt animals (Fig. 7A,B). Brains were
collected and cells dissociated and fractionated using two methods.
The first allowed the separation of a cytosol+synaptosomes
fraction from a nuclear fraction (Fig. 7A). The second separated
a cytosol+nuclei fraction from a synaptosomal fraction (Fig. 7B).
The purity of each fraction was evaluated by WB with specific
markers: postsynaptic density protein 95 (PSD95; also known as
DLG4) (cytosol+synaptosomes), histone H2B (nuclei), cyclin L1
(cytosol+nuclei), SYN1 and AMPA-selective glutamate receptor
1 (GLUR1; also known as GRIA1) (synaptosomal fraction)
(Fig. 7A,B, top). DYRK1A expression levels were assessed
following sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) of the different cellular fractions, followed by WB,
and normalization to the levels of β-actin (Fig. 7A,B, bottom).
DYRK1A was detected in all fractions in both genotypes, but its
expression was significantly higher (∼1.5-fold), in the cytosol and
synaptosomes of Tg(Dyrk1a) brains compared with those of wt
brains. No differences in nuclear DYRK1A expression were seen
between transgenic and wt animals. Brain DYRK1A overdosage in
Tg(Dyrk1a) animals thus occurs in the cytosol and synaptosomes,
but not in the nuclei. We are currently exploring the reasons for this
differential distribution of excess DYRK1A.
We next measured L41 levels in nuclear and cytoplasmic
fractions prepared from the brains of Tg(Dyrk1a) and wt animals
which had been i.p. injected daily for 19 days with L41 (20 mg/kg)
or vehicle (Fig. 7C,D). At the end of the treatments, brains were
recovered and processed for L41 extraction and quantification by
isobaric stable isotope chemical labelling, offline hydrophilic
interaction chromatography (HILIC), followed by ultra-high
precision liquid chromatography with electrospray ionization mass
spectrometry (LC–MS). Results show essentially undetectable L41 in
vehicle-treated animals, identical L41 levels in the brain nuclear
fractions of Tg(Dyrk1a) and wt animals (Fig. 7C), and a significantly
increased L41 level in the cytoplasmic fraction of Tg(Dyrk1a) brains
compared with the cytoplasmic fraction of wt animals’ brains
(Fig. 7D). Thus, DYRK1A overexpression in the transgenic animals’
brains appears to be limited to the cytoplasmic fraction,
corresponding to the subcellular distribution of overexpressed
DYRK1A (Fig. 7A,B). Accordingly, more L41 is detected in the
cytoplasmic fraction from transgenic animals compared with their
control littermates.
Phosphoproteomic effects of DYRK1A trisomy and L41
treatment reveal key synaptic and cytoskeletal components
To explore the mechanisms underlying the correcting effects of
L41 on NOR cognitive deficits of transgenic models, we analysed
the phosphoproteome of proteins isolated from the hippocampus,
cortex and cerebellum of both Tg(Dyrk1a) and Ts65Dn
models, along with their respective wt counterparts, and following
treatment with vehicle or L41 (20 mg/kg, daily i.p. injection for
19 days) (Fig. 8). All tissue samples were processed for
phosphoproteomics analysis based on the enrichment and
separation of proteotypic phosphopeptides with HILIC (see
Materials and Methods). In Tg(Dyrk1a) and Ts65Dn mice, the
hippocampus, cortex and cerebellum yielded 1384, 1523 and 2004
peptides, respectively, corresponding to 886, 948 and 1229 proteins
(Table 1; Tables S1-S13).
Among the peptides/proteins detected in this study, only 30% of
the proteins and 20% of the peptides were significantly up- or
downregulated in trisomic versus wt animals. Most peptides (80%)
were phosphorylated on serine residues, whereas phosphorylation
on threonine (15%) or tyrosine residues (5%) was less frequent.
Fig. 5. Effects of L41 treatment duration and treatment
with L43. (A-D) Wt and Tg(Dyrk1a) mice were treated
with L41 or vehicle for 5 (A), 12 (B) or 19 (C) days or L43 or
vehicle for 19 days (D). Brains were recovered and extracted,
and then DYRK1A and GSK-3α/β were immunopurified and
affinity purified, respectively, and assayed for their catalytic
activities. DYRK1A kinase activity was normalized with
GSK-3α/β activities in each extract (mean±s.e.). DYRK1A
inhibition in Tg(Dyrk1a) mice brains was not significant after
5 days of L41 treatment (P=0.42), but was increasingly
significant after 12 (P=0.04) and 19 (P=0.01) days of L41
treatment. 19 days treatment with kinase-inactive L43 did not
reduce DYRK1A activity in Tg(Dyrk1a) mice (P=0.5).
n.s., not significant. *P<0.05, **P<0.01, ***P<0.001.
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Few peptides (less than 5%) were phosphorylated on two amino
acids. Very few phosphopeptides displayed the consensus
DYRK1A phosphorylation sequence [R-P-x(1,3)-S/T-P] and
most phosphopeptides were predicted to be phosphorylated by
kinases from the CMGC (MAPK or GSK-3 protein) or AGC
[MTOR or PKG (also known as PRKG1)] groups (data obtained
with the PhosphoRS algorithm within the Proteome Discoverer
software tool, version 1.4).
We selected the phosphopeptides displaying a trisomy-
associated modulation (up- or downregulation) which was
reverted by L41 treatment (down- or upregulation) (Fig. 8).
These analyses were first run in each brain tissue and in each of the
two models and their wt controls. We thus focused on proteins
displaying an L41-reversible, trisomy-associated phosphorylation
modulation. Based on these two criteria, 258 and 248
phosphoproteins were selected from Tg(Dyrk1a) and Ts65Dn
hippocampus (Fig. 8A), respectively. Similarly, the Tg(Dyrk1a)
and Ts65Dn cortex showed 238 and 223 dysregulated
phosphoproteins, respectively (Fig. 8A). We found that 330 and
341 phosphoproteins in Tg(Dyrk1a) and Ts65Dn cerebellum,
respectively, were altered by trisomy and L41 treatment (Fig. 8A).
Among these phosphoproteins, 102, 88 and 124 were common to
both transgenic models in the hippocampus, cortex
and cerebellum, respectively (Tables S1-S12). These shared
phosphoproteins were selected for DAVID cluster analysis
(Tables S10-S12), which unravelled enrichment in synaptic,
cytoskeletal and learning pathways (Fig. 8B; Fig. S4).
ToppCluster analysis of the modulated phosphoproteins in each
model and each brain region confirmed enrichment in synaptic
transmission common to both models in the hippocampus and
cortex, while cytoskeleton organization was enriched in both
models for all three brain regions (Fig. 8B; Tables S11-S13).
We also compared, in each model, the phosphoproteins
subsets of all three brain areas (Fig. 8C). In Tg(Dyrk1a), only 16
phosphoproteins were commonly modulated in the three brain
substructures (Fig. 8C, left), while only 22 responded to these
criteria in Ts65Dn (Fig. 8C, centre). Among these 16 and 22
phosphoproteins shared by the three brain regions, only five were
common to both DS models (Fig. 8D): the microtubule-associated
proteinsMAP1A,MAP1B andMAP2, and presynaptic components
piccolo (PCLO) and SYN1. All phosphosites modulated by
both trisomy and L41 treatment, for each of the five proteins,
are schematized in Fig. S5. They illustrate the complexity of
the phosphoproteomics consequences of a single gene trisomy
[Tg(Dyrk1a)] or a partial chromosome 16 trisomy (Ts65Dn)
and the complexity resulting from the treatment with a single
Fig. 6. Persistence of the L41 inhibitory effect on DYRK1A activity and rescue of NOR deficit. (A,C) DYRK1A and GSK-3α/β activities were measured after
purification from the brains of wt (n=3), L41-treated wt (n=3), Tg(Dyrk1a) (n=3) and L41-treated Tg(Dyrk1a) (n=3) animals, 24 h (A) or 48 h (C) following the end of a
19 dayL41 treatment.After 24 h (P=0.02), but not at 48 h (P=0.93), theDYRK1Acatalyticactivityof the treatedTg(Dyrk1a)micebrainswasnormalizedcomparedwith
that of nontreated animals. (B,D) NOR tests were performed 24 h (B) or 48 h (D) after the last day of the 19 day L41 treatment. Although the rescuing effect was
detectable 24 h after the last L41 treatment (P=0.01), no rescue was seen after a 48 h delay (P=0.72). n.s., not significant. *P<0.05, **P<0.01, ***P<0.001.
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pharmacological agent. Among these five proteins, we looked for
the residues with increased phosphorylation when DYRK1A was
overexpressed, and with reduced phosphorylation when DYRK1A
was inhibited by L41, and also matching the consensus DYRK1A
phosphorylation sequence (Himpel et al., 2000). Based on these
criteria, serine 551 of SYN1 was selected for further study.
DYRK1A interacts with SYN1 and other proteins implicated
in synaptic functions
To investigate potential interactions between DYRK1A and
SYN1, co-immunoprecipitation (co-IP) experiments were carried
out with adult mouse brain lysates (Fig. 9A) using antibodies
directed against SYN1 or DYRK1A (negative control, GAPDH).
As expected, DYRK1A and SYN1 were found in their respective
immunoprecipitates (IPs). SYN1 was detected in DYRK1A IPs
and DYRK1Awas detected in SYN1 IPs (Fig. 9A), suggesting that
these proteins form a direct or indirect complex in brain extracts.
Calmodulin-dependent kinase 2A (CAMK2A) was present in
SYN1 IPs, as expected from previous results (Llinás et al., 1985;
Benfenati et al., 1992) and from its role in presynaptic vesicle pool
release (Cesca et al., 2010). CAMK2A was also detected in
DYRK1A IPs, suggesting the possibility of a DYRK1A/SYN1/
CAMK2A complex, although separate DYRK1A/CAMK2A and
SYN1/CAMK2A complexes are possible.
To see whether DYRK1A directly phosphorylates SYN1, we ran
in vitro kinase assays using recombinant DYRK1A and various
SYN1-derived peptides, including Ser551, as potential substrates, or
Woodtide as a reference substrate (Fig. 9B,C). Recombinant DYRK1A
displayed similar activity towards SYN1-tide or SYN1-S553A-tide
compared with Woodtide. In contrast, no significant phosphorylation
could be measured with the SYN1-S551A peptide. This confirms that
DYRK1A is able to phosphorylate SYN1 on its S551 residue, but not
on the nearby Ser553 site. The Ser551 site matches with the consensus
DYRK1A phosphorylation site (Fig. 9B).
DISCUSSION
Rescue of cognitive deficits by pharmacological inhibition
of excess DYRK1A
In this study, we show that trisomy is associated with an increase in
DYRK1A expression and catalytic activity, and that a class of
Fig. 7. DYRK1A and L41 subcellular localization. (A,B) Wt or Tg(Dyrk1a) brains were fractionated by two methods and the expression of DYRKA was
estimated by WB following SDS-PAGE. Reference subcompartment-specific proteins were detected by WB. (A) DYRK1A expression in cytoplasm+
synaptosomes and in nuclear fractions [wt, n=6; Tg(Dyrk1a), n=6]. DYRK1A overexpression is observed in the cytoplasm+synaptosomes fraction (P=0.006),
but not in the nuclear fraction (P=0.9). WB of specific markers validates the purity of fractions: PSD95 (95 kDa, cytoplasmic+synaptosomal marker), H2B
(17 kDa, nuclear marker), β-actin (42 kDa, housekeeping protein). (B) DYRK1A expression in cytoplasm+nuclei and in synaptosomal fractions [wt, n=7;
Tg(Dyrk1a), n=7]. DYRK1A was overexpressed in both cytoplasmic+nuclear (P=0.001) and synaptosomal (P=0.02) fractions. Fractionation was confirmed
by WB of specific compartment markers: cyclin L1 (55 kDa, cytoplasmic+nuclear marker), GLUR1 (100 kDa, postsynaptic marker), SYN1 (74 kDa, presynaptic
marker), β-actin (42 kDa, housekeeping protein). (C,D) L41 subcellular levels. L41 was more highly detected in the brain nuclear (C) and cytoplasmic
(D) compartments in L41-treated wt (n=5) and Tg(Dyrk1a) (n=2) mice compared with nontreated wt (n=5) and nontreated Tg(Dyrk1a) (n=5) mice. L41 distribution
was not significantly different between the brain nuclear fractions of treated wt and Tg mice. In contrast, the L41 level was increased in the cytoplasm of
treated Tg mice brain compared with the cytoplasm of control wt mice brain (P=0.002). n.s., not significant. *P<0.05, **P<0.01, ***P<0.001.
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synthetic DYRK1A inhibitors, the leucettines, exemplified by L41,
is able to cross the blood brain barrier and selectively inhibit
the excess DYRK1A linked to trisomy. Why only this fraction
of overexpressed DYRK1A is inhibited, and most native, basal
DYRK1A is not, remains a mystery. This effect could be linked to
the accumulation of excess DYRK1A and L41 in specific cellular
compartments and not in others, as shown in Fig. 7. Intriguingly,
a similar sensitivity to inhibition of excess DYRK1A compared
with ‘normal’ DYRK1A was observed with EGCG. This finding is
encouraging in terms of potential therapeutic implications, as
complete inhibition of DYRK1A is not desired. Intracellular
DYRK1A has been described in both nuclear and cytoplasm
compartments (Martí et al., 2003). Our results indicate that it is also
present in synaptosomes, which might have consequences on the
regulation of synaptic vesicles trafficking (see below).
We here demonstrate the rescuing effect of synthetic DYRK1A
inhibitors, leucettines L41 and L99, on deficient recognition
memory of three different trisomic mouse models with increasing
genetic complexity, Tg(Dyrk1a), Ts65Dn and Dp1Yey. These
beneficial behavioural effects directly correlate with inhibition
of excess DYRK1A activity. There is also a strong coincidence
with the duration of the drug treatment (Figs 2A and 5), the
potency of the leucettine analogues (Figs 2B and 5) and
the duration of the drug-free period following the last injection
(Fig. 6). Finally, behavioural correcting benefits detected in the
NOR test (Figs 2 and 6) correlate with remodelling of brain
functional connectivity detected by fMRI (Fig. 3). However, we
observed that working and spatial memories impaired in the
Tg(Dyrk1a) mice were insensitive to L41 treatment, as assessed in
the Y-maze and place object location tasks, respectively. This
indicates a specific action of DYRK1A inhibition on molecular
pathways specifically related to recognition memory. Our findings
further strengthen the essential role of DYRK1A in intellectual
phenotypes associated with DS. Leucettine derivatives should thus
Fig. 8. Phosphoproteomic analysis of Tg(Dyrk1a) and Ts65Dn mice brains following exposure to L41. Phosphoproteins, in each brain substructure,
that are both up- or downregulated by trisomy and, respectively, down- and upregulated by L41 treatment were selected for analysis. (A) Venn diagrams
comparing the two transgenic models versus wt and L41 treatment, at tissue level. 102, 88 and 124 modified phosphoproteins were common to the two models
in the hippocampus, cortex and cerebellum, respectively. Numbers in parentheses indicate dual modulated phosphoproteins in each model and each tissue.
(B) Biological processes enrichment deregulated by the phosphoproteins which are modulated one way in both Tg(Dyrk1a) and Ts65Dn mice and affected by
L41 treatment in the opposite way. Represented here are those common to both models and to the three brain tissues. DAVID and ToppCluster analyses
were performed in the hippocampus, cortex and cerebellum separately. Enriched classification is determined by the –log(P-value). Synaptic transmission,
common to the hippocampus and cortex, and cytoskeleton organization, common to the three brain regions, are the processes most modified by trisomy and
sensitive to L41. (C) Venn diagrams illustrate the number of dually modulated phosphoproteins in each model and in each tissue, and the numbers shared by
different brain areas. 16 and 22 proteins were shared by all three tissues in Tg(Dyrk1a) and Ts65Dnmice, respectively. (D) Venn diagram comparison of these 16
and 22 phosphoproteins revealed that five are shared by both models.
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be investigated further as drug candidates to improve cognitive
functions of DS patients.
L41 treatment in DYRK1A-overexpressing mice triggers
remodelling of brain FC pathways
Brain rsfMRI in Dp1Yey mice revealed global resilience
of functional cerebral circuitry after L41 administration.
Notably, L41 corrected the abnormal DMN patterns found in
Dp1Yey mice, but also acted on connectivity of key brain areas
associated with cognitive and memory processing (PFC, ACA,
PERI, HF). DMN (Raichle, 2015) – previously described as a
highly active circuitry during rest – and preserved across species
(Stafford et al., 2014), was shown to be vulnerable to various
neuropathological conditions (Hawellek et al., 2011; Raichle, 2015;
Zhou et al., 2017), including DS (Anderson et al., 2013; Pujol et al.,
2015). The core area of this network in mice is the RSP (associated
Table 1. Summary of phosphoproteomic analyses
Model
Tg(Dyrk1a) Ts65Dn Common
Brain area Hippocampus Cortex Cerebellum Hippocampus Cortex Cerebellum Hippocampus Cortex Cerebellum
Total protein number 886 948 1229 886 948 1229 – – –
Total peptide number 1384 1523 2004 1384 1523 2004 – – –
Modulated proteins, trisomic vs wt 275 256 364 257 230 365 – – –
Modulated peptides, trisomic vs wt 333 296 437 311 270 422 – – –
Modulated proteins, trisomic, L41 vs vehicle 267 240 344 253 228 355 34 38 59
Modulated peptides trisomic, L41 vs vehicle 321 275 403 307 265 410 40 38 63
Phospho-Ser peptides 265 221 333 246 205 320 33 29 51
Phospho-Thr peptides 39 44 58 53 42 75 6 6 11
Phospho-Tyr peptides 17 10 12 8 18 15 1 3 1
Phospho-Ser and phospho-Thr peptides 18 19 23 10 6 24 – – –
Phospho-Ser and phospho-Tyr peptides 5 1 4 2 3 4 – – –
Phospho-Thr and phospho-Tyr peptides 6 1 4 7 4 2 – – –
DYRK1A phosphorylation sites 1 7 8 6 3 6 – – –
Other kinases’ phosphorylation sites 279 251 383 263 223 351 – – –
Fig. 9. Direct interaction of DYRK1A and SYN1, phosphorylation of SYN1 by DYRK1A. (A) DYRK1A and SYN1 were immunoblotted following
immunoprecipitation from wt mice brain extracts. DYRK1A or SYN1 present in the starting material (Input) were recovered in the IPs. SYN1 (74 kDa) was present
in the DYRK1A IP and DYRK1A (85 kDa) was detected in the SYN1 IP, suggesting that these two proteins interact directly. Positive control of the SYN1 IP was
performed using an anti-CAMKII antibody. As expected, CAMKII (50 kDa) was present in the SYN1 IP. DYRK1A IP also brought down CAMKII, suggesting
complexes between SYN1, CAMKII and DYRK1A. (B) Sequence of SYN1 in the vicinity of Ser551 matches with the consensus DYRK1A phosphorylation site.
Based on this sequence, three peptides were synthesized and used as potential substrates: SYN1, SYN1-S551A and SYN1-S553A. (C) Kinase activity of
recombinant DYRK1A towards the three different SYN1peptides. SYN1 and SYN1-S553A peptides were phosphorylated at the same level as Woodtide by
recombinant DYRK1A (71.7%±5.2%, 70.1% and 78.4%±11.4%, respectively). No significant catalytic activity was measured with the SYN1-S551A peptide
(7.9%±1.2%).
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with the posterior cingulate/precuneus cortex in humans) (Hübner
et al., 2017; Sforazzini et al., 2014). Our analysis unravelled
increased local connectivity around the RSP in DS mice, but
strongly reduced long-range communication with frontocortical
brain regions (ACA, PFC; Fig. S3), when compared with wt
animals. This short-range stronger connectivity is not limited to
the RSP, but represented a common feature for other investigated
brain regions (ACA, PERI, HF) of Dp1Yey mice. Such a pattern of
increased local, short-range brain communication was described
as a cardinal feature of FC in DS patients (Anderson et al., 2013;
Pujol et al., 2015; Vega et al., 2015). Indeed, DS human brains are
characterized by simplified network structure, organized by local
connectivity (Anderson et al., 2013; Pujol et al., 2015; Vega et al.,
2015) and impaired efficiency to integrate information from
distant connections.
Dp1Yey mouse brains additionally displayed features of higher
negative functional correlations as compared with the wt vehicle
group and, more obviously, a reversed correlation pattern (switch
from positive to negative correlations) between the RSP and frontal
cortical areas in the DS model. This feature, attenuated or corrected
following L41 treatment, could eventually be discussed in the context
of L41 regulation of inhibition/excitation ratios, imbalanced in
DYRK1A-overexpressing mice (Souchet et al., 2014). Indeed,
increased number and signal intensity from neurons expressing
GAD67 (also known as GAD1), an enzyme that synthesizes GABA,
indicating inhibition pathway alterations, was quantified in three
different DS models (Souchet et al., 2014), including Dp1Yey.
Pharmacological correction of inhibition/excitation was achieved in
the Tg(Dyrk1a) DS mouse model (Souchet et al., 2015) by EGCG
treatment. We can speculate on a similar effect of L41 on inhibition/
excitation balance, and subsequent modulation of brain connectivity.
Nevertheless, the brain synchrony modifications after L41 inhibition
of excess DYRK1A activity in DS models might potentially reflect
other molecular mechanisms and interactions at the synaptic and
cytoskeletal level, as shown here, and subsequently underpin
correction of cognitive and memory deficits of DS mice.
Importantly, L41 had only limited effects on FC in wt animals,
whereas in the Dp1Yey model it largely impacted the connectivity
features, on distributed action sites, that coincide with alterations
reported for brain anatomy in DS models, most notably, frontal
and prefrontal cortical areas (ACA/PFA), the HF, PAL and TH.
Volumetric MRI in DS mouse models, showed a general trend for
smaller frontal lobes, hippocampal and cerebellar regions, but
larger thalamic and hypothalamic areas (Powell et al., 2016;
Roubertoux et al., 2017). Diffusion MRI also identified potential
microstructural alterations in the above-mentioned areas and also
the striatum (including the PAL) (Nie et al., 2015). Our rsfMRI
study advances the current knowledge on the brain functional
communication in DSmousemodels, revealing targeted and effective
action of L41 on brain circuitry, consistent with the profile of
cognitive and novel object recognition memory improvements.
DYRK1A and SYN1
Phosphoproteomic analyses using ultra-high precision LC–MS
analysis unravelled several clusters of neuronal phosphorylated
proteins directly controlled by DYRK1A or clusters indirectly
modulated in the trisomic condition and sensitive to L41 treatment.
Five phosphoproteins were shared by Tg(Dyrk1a) and Ts65Dn
mice and were present in three brain substructures (hippocampus,
cortex, cerebellum) (Fig. 8). Furthermore, these phosphoproteins
showed significant modulation in their phosphorylation levels in
trisomic versus disomic animals and these modulations were
sensitive, in the opposite direction, to L41 treatment. A few key
pathways, including controlling synaptic vesicle (SV) transport,
calcineurin NFAT signalling and cytoskeleton organization, were
found to be directly affected by DYRK1A, or as a consequence of its
kinase activity (Fig. S4), while others might represent indirect
effects of the overdosage. Nevertheless, the immune response was
found to be affected, correlating with several studies linking
DYRK1A to inflammation. We here focused on SYN1 as it was the
only protein that revealed a serine residue corresponding to the
DYRK1A phosphorylation consensus sequence. SYN1 Ser551
was hyperphosphorylated following DYRK1A overexpression and
dephosphorylated following L41 treatment. Representative annotated
ultra-high resolution product ion spectrum of proteotypic peptide
qSRPVAGGPGAPPAARPPAsPSPqR encoding the phosphorylated
residue Ser551 is shown in Fig. S6.
Co-IP experiments showed that DYRK1A interacts, either directly
or indirectly, with SYN1 (Fig. 9). SYN1 has been described to be
involved in the reserve SV pool maintenance at the presynaptic
bouton by tethering SVs to the actin cytoskeleton (Hilfiker et al.,
2005; Benfenati et al., 1991). Phosphorylation of SYN1 by CAMKII
leads to the release of SVs and allows them tomove close to the active
zone (Llinás et al., 1991). Neurotransmitter release at the active zone
is thus strongly dependent on SYN1 phosphorylation. We showed
that SYN1 was phosphorylated by DYRK1A on its S551 residue
in vitro and in vivo, thus highlighting a novel role of DYRK1A
in SYN1-dependent presynaptic vesicle trafficking. Besides its
physiological role in synaptic plasticity regulation, SYN1 has been
associated with epilepsy (Garcia et al., 2004; Fassio et al., 2011).
Mutations in the phosphorylation domains of SYN1 essential for
vesicle recycling control have been related to epilepsy (Fassio
et al., 2011). In addition, mental retardation, autosomal dominant
7 (MRD7) patients with Dyrk1a haploinsufficiency display epilepsy
seizures (Courcet et al., 2012; Møller et al., 2008; Oegema et al.,
2010; Valetto et al., 2012; Yamamoto et al., 2011). Our results
suggest that epileptic seizures observed in MRD7 patients could be
induced by defects in SYN1 regulation.
DYRK1A, microtubule-binding proteins, PCLO and other
synaptic targets
The other four proteins found in our phosphoproteomics study will
be the object of another study but are briefly reviewed here. The
detection of MAP1A, MAP1B and MAP2, all previously reported
as DYRK1A substrates (Murakami et al., 2012; Scales et al.,
2009), validated the power of our analysis and confirmed the
role of DYRK1A in dendrite morphogenesis and microtubule
regulation (Ori-McKenney et al., 2016). The last phosphoprotein,
PCLO, is a cytoskeletal matrix protein associated with the
presynaptic active zone (Cases-Langhoff et al., 1996), which
acts as a scaffolding protein implicated in SV endocytosis
and exocytosis (Garner et al., 2000; Fenster et al., 2003). The
lack of PCLO in the human brain leads to a dramatic neuronal
loss associated with pontocerebellar hypoplasia type III (Ahmed
et al., 2015). Moreover, PCLO knockdown in cultured
hippocampal neurons increases SYN1 dispersion out of the
presynaptic terminal and SV exocytosis (Leal-Ortiz et al., 2008).
It has been shown that PCLO modulates neurotransmitter release by
regulating F-actin assembly (Waites et al., 2011). It clearly appears
that PCLO acts upstream of SYN1 and regulates its role in vesicle
recycling.
Taken together, our findings reveal SYN1 as a new direct
substrate of DYRK1A, suggesting a novel role of this kinase in the
regulation of SV release at the presynaptic terminal. Moreover, the
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relatively safe and selective DYRK1A inhibitors, the leucettines,
successfully correct recognition memory deficits associated with
DS in three different mice models. Although the DYRK1A-
dependent biological process which is rescued by these drugs still
needs to be elucidated, leucettines and their analogues represent
promising therapeutic drugs to enhance cognitive functions in DS
patients.
DYRK1A, DS and AD
There is strong support for the involvement of DYRK1A
in cognitive deficits associated with Alzheimer’s disease (AD):
(1) DYRK1A mRNA (Kimura et al., 2007) and DYRK1A protein
(Ferrer et al., 2005) levels are increased in postmortem human AD
brains compared with healthy brains; (2) calpain 1-induced cleavage
of DYRK1A is observed in AD brains and associated with increased
activity (Jin et al., 2015); (3) DYRK1A phosphorylates key AD
players, such as amyloid precursor protein (Ryoo et al., 2008),
presenilin 1 (Ryu et al., 2010), Tau (also known as MAPT) (Woods
et al., 2001; Ryoo et al., 2007; Azorsa et al., 2010; Coutadeur et al.,
2015; Jin et al., 2015), septin (Sitz et al., 2008) and neprylysin
(Kawakubo et al., 2017); (4) DYRK1A regulates splicing of
Tau mRNA (Shi et al., 2008; Wegiel et al., 2011; Yin et al., 2012,
2017; Jin et al., 2015); (5) DYRK1A inhibition corrects cognitive
defects in 3xTG-AD (Branca et al., 2017), APP/PS1 (B. Souchet,
unpublished) and Aβ25-35 peptide-injected wt mice (Naert et al.,
2015), three widely used mice models of AD. These facts provide
additional incentive to investigate the regulation and substrates
of brain DYRK1A and to develop potent and selective DYRK1A
inhibitors to treat cognitive deficits observed in different
indications. DS patients display early symptoms of AD and show
a high frequency of dementia at later age (Ballard et al., 2016). The
triplication of APP located on the HSA21 is thought to contribute to
amyloid plaques and neurofibrillary tangles, two causative factors
in AD, that accumulate early in 30- to 40-year-old DS people (Head,
et al., 2012a). These factors, associated with neuroinflammation and
oxidative damage also diagnosed in both AD and DS individuals,
lead to precocious dementia observed from age 30 to 39 (Head et al.,
2012b). Studying DS will have an impact on the understanding of
AD and, reciprocally, DYRK1A is clearly a common factor between
the two diseases.
MATERIALS AND METHODS
Animal models, treatment and behaviour assessment
Tg(Dyrk1a) mutant mice and Dp1Yey models were maintained on the
C57BL/6J genetic background. Ts(1716)65Dn trisomic mice were obtained
from The Jackson Laboratory and kept on the C57BL/6J×C3B, a congenic
sighted line for the BALB/c allele at the Pde6b locus (Hoelter et al., 2008).
The local ethics committee, Com’Eth (no. 17), approved all mouse
experimental procedures, under the accreditation number APAFIS #5331
and #3473, with Y.H. as the principal investigator.
Behavioural studies were conducted in 12- to 20-week-old male animals.
All assessments were scored blind to genotype and treatment, as
recommended by the ARRIVE guidelines (Karp et al., 2015; Kilkenny
et al., 2010). Leucettine L41 was prepared at 40 mg/ml in dimethyl
sulfoxide (DMSO), aliquoted and stored below −20°C. The final formulation
was prepared just prior to use as a 2 mg/ml solution diluted in PEG300/water
(50/45), to reach a final DMSO/PEG300/water 5/50/45 (v/v/v) mix.
Treated animals received a daily dose (5, 12 or 19 days) of this formulation
by i.p. injection of 20 mg/kg/day. Nontreated animals received the same
formulation without L41.
The NOR task is based on the innate tendency of rodents to differentially
explore a novel object over a familiar one (Ennaceur and Delacour, 1988).
Day 1 was a habituation session. Mice freely explored the apparatus, a white
circular arena (53 cm diameter) placed in a dimly lit testing room (40 lux).
On day 2, the acquisition phase, mice were free to explore two identical
objects for 10 min. Mice were then returned to their home cage for a 24 h
retention interval. To test their memory, on day 3, one familiar object
(already explored during the acquisition phase) and one novel object were
placed in the apparatus and mice were free to explore the two objects for a
10 min period. Between trials and subjects, the different objects were
cleaned with 50° ethanol to reduce olfactory cues. To avoid a preference for
one of the objects, the new object was different for different animal groups
and counterbalanced between genotype and treatment as well as for location
of novel and familiar objects (left or right). Object exploration was manually
scored and defined as the orientation of the nose to the object at a distance
<1 cm. For the retention phase, the percent of time spent exploring familiar
versus novel objects was calculated to assess memory performance.
rsfMRI
rsfMRI was performed on 26 animals separated into four groups: wt, vehicle
treated; wt, L41 treated; Dp1Yey, vehicle treated; Dp1Yey, L41 treated.
rsfMRI was carried under medetomidine sedation during scanning
[subcutaneous bolus injection, 0.3 mg/kg in 100 µl 0.9% NaCl solution
right before the scan followed by continuous subcutaneous infusion
of medetomidine (0.6 mg/kg, 200 µl/h)]. Physiological parameters were
continuously monitored. rsfMRI data were collected using a 7 T small bore
animal scanner and a mouse head adapted cryocoil (Biospec 70/20 andMRI
CryoProbe, Bruker, Germany). The whole brain was examined [24 slices;
150×150×700 μm3 spatial resolution) using single shot gradient echo
EPI (echo time/repetition time=10 ms/1700 ms)] and 200 volumes were
recorded. The preprocessing included motion correction, data co-
registration with Allen Mouse Brain Atlas (mouse.brain-map.org),
detrending, band pass filtering (0.01-0.1 Hz) and regression of ventricular
signal. For seed-based correlation analysis, the functional connectivity of
several brain areas was mapped: RSP to map the default mode network, CA1,
DG, PERI and anterior cingulate area (ACC). Correlation coefficients were
then computed (two-tailed Student’s t-test, P<0.001) between the seed region
and the averaged BOLD signal time series of the remaining whole brain for
each group and were converted and mapped to z-values using Fisher’s r-to-z
transformation.
DYRK1A and GSK-3β protein levels
Brains were obtained from mice and snap-frozen until further use. Then
tissues were weighed, homogenized and sonicated in 1 ml lysis buffer
(60 mM β-glycerophosphate, 15 mM p-nitrophenylphosphate, 25 mM
Mops pH 7.2, 15 mM EGTA, 15 mM MgCl2, 2 mM dithiothreitol, 1 mM
sodium orthovanadate, 1 mM sodium fluoride, 1 mM phenylphosphate
disodium and protease inhibitor cocktail) per g of material. Homogenates
were centrifuged for 15 min at 17,000 g and 4°C. The supernatant was
recovered and assayed for protein content (Bio-Rad, France). The proteins
were separated by 10% NuPAGE pre-cast Bis-Tris polyacrylamide mini gel
electrophoresis (Invitrogen, France) with MOPS-SDS running buffer.
Proteins were transferred to 0.45-µm nitrocellulose filters (Schleicher
and Schuell, Germany). They were blocked with 5% low-fat milk in
Tris-buffered vehicle/Tween 20, and incubated overnight at 4°C with
antibodies. Anti-DYRK1A (H00001859-M01; 1:1000) and anti-GSK-3α/β
(KAM-ST002E; 1:1000) were obtained from Interchim (France) and
Stressgen (France), respectively. Appropriate secondary antibodies
conjugated to horseradish peroxidase (Bio-Rad) were added to visualize
the proteins using the enhanced chemiluminescence reaction (ECL,
Amersham, France).
Protein kinase assays
Protein kinase assays to measure the catalytic activity of DYRK1A in the
brains of the animals treated with or without drugs were performed as follows:
frozen half brains were homogenized in lysis buffer (1.2 ml/half brain) using
Precellys® homogenizer tubes. After centrifugation at 2800 g for 2×15 s,
1 mg brain extract was incubated with 2 µg DYRK1A (H00001859 M01,
Interchim) or GSK3-β (MBS8508391, Emelca Bioscience, France)
antibodies at 4°C for 1 h under gentle rotation. Then, 20 µl protein G
agarose beads (Thermo Fisher Scientific, France), previously washed three
times with bead buffer (50 mM Tris pH 7.4, 5 mM NaF, 250 mM NaCl,
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5 mM EDTA, 5 mM EGTA, 0.1% Nonidet P-40 and protease inhibitor
cocktail from Roche, France), were added to the mix and gently rotated
at 4°C for 30 min. After a 1 min spin at 10,000 g and removal of the
supernatant, the pelleted immune complexes were washed three times with
bead buffer, and a last time with Buffer C (60 mM β-glycerophosphate,
30 mM p-nitrophenolphosphate, 25 mM Mops pH 7.2, 5 mM EGTA,
15 mM MgCl2, 2 mM dithiothreitol, 0.1 mM sodium orthovanadate,
1 mM phenylphosphate, protease inhibitor cocktail). DYRK1A or GSK-3
immobilized on beads were assayed in buffer C as described in the
SupplementaryMaterials andMethods withWoodtide (KKISGRLSPIMTEQ)
(1.5 µg/assay) or GSK3-tide (YRRAAVPPSPSLSRHSSPHQpSED-EEE,
where pS stands for phosphorylated serine) as substrates.
Protein kinase assays to evaluate SYN1 phosphorylation by DYRK1A
were performed with 50 ng recombinant DYRK1A protein (PV3785,
Thermo Fisher Scientific) and 0.98 mM Woodtide, and three peptides
derived from the SYN1 putative DYRK1A phosphorylation site (Fig. 9C).
Kinase activity was then measured as described in the Supplementary
Materials and Methods.
The selectivity of the three leucettines used in this study was evaluated
in a panel of 16 recombinant protein kinases assayed as described in the
Supplementary Materials and Methods.
Subcellular fractionation
Nuclear, cytosolic and synaptosomal subcellular fractionation of brain
tissue was performed with the Syn-PER™ and ProteoExtract® Tissue
Dissociation Buffer Kit and Subcellular Proteome Extraction Kit following
the instructions of the manufacturer. Fractions were analysed by SDS-PAGE
and WB with specific antibodies.
Phosphoproteomics results analysis
Gene ontology enrichment analyses of phosphoproteins that are modulated
(up- or downregulated) in Tg(Dyrk1a) or Ts65Dn mice versus wt and also
modulated in the opposite manner (down- or upregulated) by the L41
treatment, were conducted using ToppCluster (Bonferroni correction,
P-value cutoff 0.05). Only biological processes common to the three
brain regions and both models are presented (complete biological processes
are listed in Tables S11-S13).
DYRK1A substrates and their respective phosphorylation sites were
identified in the phosphoproteome based on the DYRK1A phosphorylation
consensus sequence R-P-x(1,3)-S/T-P (Himpel et al., 2000). Protein-protein
interactions of each substrate were generated with STRING web server
application. Biological process enrichments of each cluster were assessed by
using ToppCluster web server application. Phospho-network was mapped
with the Cytoscape tool. See Supplementary Materials and Methods
for details.
Immunoprecipitation and immunoblotting
All immunoprecipitations were performed on fresh half brains of 3-month-
old wt male mice. Brains were dissected and lysed in 1.2 ml RIPA lysis
buffer (Santa-Cruz Biotechnology, France) using Precellys® homogenizer
tubes. After centrifugation at 2800 g for 2×15 s, 1 ml brain extract was
incubated with 2 µg of antibody of interest at 4°C for 1 h under gentle
rotation. An aliquot of the remaining supernatant was kept for further
immunoblotting as homogenate control. Then, 20 µl protein G agarose
beads, previously washed three times with bead buffer, were added to the
mix and gently rotated at 4°C for 30 min. After a 1 min spin at 10,000 g and
removal of the supernatant, the pelleted immune complexes were washed
three times with bead buffer beforeWB analysis with appropriate antibodies
directed against DYRK1A (H00001859 M01, Interchim; 1:1000), PSD95
(ab18258, Abcam, France; 1:1000), SYN1 (ab64581, Abcam; 1:1000),
CAMK2A (PA5-14315, Thermo Fisher Scientific; 1:1000) and GAPDH
(MA5-15738, Thermo Fisher Scientific; 1:3000). Immunoblots were
revealed with Clarity Western ECL Substrate (Bio-Rad).
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Altafaj, X., Martıń, E. D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrıń, C.,
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Fitó, M., Benejam, B., Langohr, K., Rodriguez, J. et al. (2014).
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in
Down syndromemousemodels and in humans.Mol. Nutr. FoodRes. 58, 278-288.
de la Torre, R., de Sola, S., Hernandez, G., Farré, M., Pujol, J., Rodriguez, J.,
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